Pliant Q3 Loss Narrows to $24.4M; Discloses Nasdaq $1.00 Bid-Price Deficiency
PLRX is trading near its 52-week low of $0.733 (6.5% above the low).
Summary
Pliant's Q3 net loss narrowed to $24.4M from $26.3M, but cash dropped to $142.6M and the filing newly discloses the stock has traded below Nasdaq's $1.00 minimum bid since October 9, 2026.
Key Events · Earnings and Guidance · PLRX
-
Q3 Loss Narrows on Cost Cuts
Net loss was $24.4M versus $26.3M a year earlier; R&D was flat at $17.9M and G&A fell $2.5M to $7.8M after the 2025 restructuring.
-
Cash Falls to $142.6M
Cash, cash equivalents, short-term investments and restricted cash dropped from $192.4M at December 31, 2025 to $142.6M at September 30, 2026; nine-month operating cash burn was $49.0M versus $110.5M a year earlier.
-
Nasdaq Bid-Price Deficiency Disclosed
The stock closed at $0.80 on November 9, 2026 and has not closed above $1.00 since October 9, 2026, putting the company below Nasdaq's minimum bid price requirement.
-
FORTIFY Enrollment Ahead of Schedule
The Phase 1b trial of PLN-101095 plus pembrolizumab is enrolling ahead of plan across NSCLC, ccRCC and high-TMB cohorts, with interim data expected in 2027.
Analysis · PLRX · Life Sciences
The quarter itself is unremarkable — R&D held flat at $17.9M and G&A fell $2.5M to $7.8M on lower headcount, so the net loss narrowed to $24.4M from $26.3M. What matters is the balance sheet and the listing risk. Cash, equivalents, short-term investments and restricted cash fell to $142.6M from $192.4M at year-end 2025, and management still says that funds operations for the next 12 months and beyond, but the company now also discloses that its stock closed at $0.80 on November 9, 2026 and has not closed above $1.00 since October 9, 2026 — a Nasdaq minimum bid price problem that did not appear in the prior quarter's baseline. With a $50.0M at-the-market program in place and unused, any equity raise at sub-$1 prices would be heavily dilutive, and a reverse split becomes a live possibility to cure the deficiency.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 37% of the 3595 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PLRX was trading at $0.78 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $45.8M. The 52-week trading range was $0.73 to $1.82. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.